Chromosomal Abnormalities Associated with Clinical Outcome in Patients with Newly Diagnosed Multiple Myeloma / 中国实验血液学杂志

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the prognostic value of karyotypic abnormalities in evaluation of prognosis of patients with multiple myeloma.</p><p><b>METHODS</b>The clinical and laboratory data of patients with newly diagnosed multiple myeloma (NDMM) were retrospectively analyzed in our hospital from May 2010 to May 2016. Patients who carried t(4; 14), t(14; 16) or 17P (at least one of them) were defined as the patients with high-risk karyotype, whereas patients characterized by the absence of the above-mentioned abnormalities were defined as patients with standard-risk karyotype. PFS (progression-free survival, PFS) and OS (over all survival, OS) time was compared between the 2 groups.</p><p><b>RESULTS</b>There were 110 cases in the high-risk group, and 302 cases in the standard-risk group. The clinical characteristics, such as age, sex, ISS stage and treatment regimen etc were not statistically different between 2 groups. The median OS time of patients in the high-risk and standard-risk groups were 42 months (CI 95% 34.375-49.625 months) and 53 months (CI 95% 46.310-59.690 months) (P<0.05). The median PFS time of patients in the high-risk group and standard-risk groups was 21 months (CI95% 17.198-24.802 months) and 27 months (CI95% 23.406-30.594 months) (P<0.05).</p><p><b>CONCLUSION</b>Among patients with newly diagnosed MM, the PFS and OS time in the patients with high-risk karyotype is shorter than that in patients with standard-risk karyotyp.</p>